Patricia Coyle from Stony Brook Medicine: Teri-PRO Trial shows Continued Benefits of Aubagio

Video

When a medication is approved the data from that time can sometimes be of more value than the trials leading up to the approval. For Aubagio there was a recent study done looking at patient satisfaction and other issues following the approval.

When a medication is approved the data from that time can sometimes be of more value than the trials leading up to the approval. For Aubagio there was a recent study done looking at patient satisfaction and other issues following the approval.

Patricia K. Coyle, MD, from Stony Brook Medicine discussed the results of the Teri-PRO trial during the annual ECTRIMS conference in London. Coyle noted that the results focused more on patient reported results and issues than earlier trials. Through one year of research Coyle said there were definite benefits shown which was encouraging not only to the patients but also their providers as well.

Related Videos
Ankeet Bhatt, MD, MBA | Credit: X.com
Sara Saberi, MD | Credit: University of Michigan
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Veraprapas Kittipibul, MD | Credit: X.com
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Building a Psoriasis Knockout Regimen Around Risankizumab, with Andrew Blauvelt, MD, MBA
Joel Gelfand, MD, MSCE: Phototherapy Utility in Psoriasis
© 2024 MJH Life Sciences

All rights reserved.